Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity
Bayer’s ophthalmology pipeline has long been dominated by the blockbuster drug Eylea® (aflibercept), co-marketed with Regeneron Pharmaceuticals and initially approved in 2011. However, Eylea is close to losing exclusivity for key U.S. patents. The post Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News.
📰 Original Source
Read full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.